Get the Daily Brief

All action, no filler. BioBriefs delivers biotech’s 10 must-know updates, every morning.

Latest Biotech News

FDA Approves Merck’s RSV Antibody For Infant Use Amid Advisory Shakeup

June 10, 2025

The FDA granted approval to Merck's monoclonal antibody drug Enflonsia for preventing respiratory syncytial virus (RSV) infections in infants under 12 months. The drug is priced competitively...

Metsera’s Long-Acting Amylin Analog Shows Promising Obesity Trial Results

June 10, 2025

Metsera reported encouraging phase I data for its long-acting amylin analogue MET-233i, indicating dose-dependent weight loss efficacy and potential for once-monthly dosing. The therapy exhibited...

Merck's Oral PCSK9 Inhibitor Advances With Dual Phase III Success

June 10, 2025

Merck announced successful outcomes from two phase III studies evaluating its oral PCSK9 inhibitor, enlicitide decanoate, in patients with high cholesterol on statin therapy. The drug demonstrated...

Recursion Cuts 20% of Staff Following Pipeline Restructuring

June 10, 2025

Recursion Pharmaceuticals disclosed a 20% reduction in workforce following a recent decision to narrow its research focus and deprioritize multiple clinical-stage programs. This downsizing...

Merck’s RSV Antibody Enters Market While CDC Vaccine Advisory Panel Is Reconstituted

June 10, 2025

Merck received FDA approval for its RSV antibody drug, Enflonsia, targeting infants under 12 months and directly competing with Sanofi and AstraZeneca’s Beyfortus. The approval occurs amid a...

Biotech Industry Financial and Corporate Movements

June 10, 2025

Biotech firms navigate financial turbulence and strategic deals amid sector-wide shifts. Recursion Pharmaceuticals announced 20% workforce layoffs linked to clinical pipeline cuts after merging...

Novel Technologies in Diagnostics and Therapeutics

June 10, 2025

Innovations span diagnostics and treatment modalities, including AI-powered rapid viral detection via nanopore technology, promising faster clinical decisions. Linear Diagnostics secured £1M UK...

Emerging Regulatory and NIH Funding Challenges in Biotech Research

June 10, 2025

The biotech community faces mounting challenges from politicization and funding cuts. Researchers issued the Bethesda Declaration urging restoration of NIH grants delayed or terminated under the...

Alzheimer’s and Neurodegenerative Disease Advances

June 10, 2025

Multiple studies illuminate neurodegenerative disease mechanisms and diagnosis. Dr. Sophia Shi detailed how sugar molecule degradation in the brain’s glycocalyx contributes to aging and...

Innovations in Bioprinting and Tissue Engineering Materials

June 10, 2025

Researchers at Stony Brook University developed TRACE (Tunable Rapid Assembly of Collagenous Elements), a novel collagen bioprinting method enabling instant assembly of physiological collagen...

Breakthroughs in Cancer Diagnostics and Therapeutics

June 10, 2025

Recent studies advance cancer care with novel diagnostic and therapeutic approaches. Indiana University secured FDA clearance for the first blood test detecting Alzheimer’s amyloid pathology,...

AI Advances Enhance Drug Discovery and Genetic Insights

June 10, 2025

Biotech and academic researchers harness artificial intelligence to unravel genetic networks and streamline drug discovery. Northwestern University developed TWAVE, an AI tool identifying gene...

Metsera's Amylin Analogue Shows Promise for Obesity Treatment

June 10, 2025

Metsera Inc. released early clinical data indicating their long-acting amylin analogue, MET-233i, induces significant dose-dependent weight loss with an extended half-life supporting once-monthly...

Oral PCSK9 Inhibitors Demonstrate Efficacy in Late-Stage Trials

June 10, 2025

Merck & Co. reported positive results from two Phase III trials of their oral PCSK9 inhibitor enlicitide decanoate, achieving statistically significant reductions in LDL cholesterol in patients...

FDA Approves Competing RSV Antibody Drugs Amid Advisory Committee Overhaul

June 10, 2025

Merck's RSV antibody drug Enflonsia has received FDA approval for infants under 12 months, entering a market dominated by Sanofi and AstraZeneca's Beyfortus. This approval coincides with the...